The $40 million, broadly speaking, that is going to go to CanCOGeN is split into two pieces. There's a viral sequencing element and a human sequencing element.
On the viral sequencing element, it's really designed to do two major things. One is to use the mutations that accumulate in the virus as it's being transmitted to be able to, in effect, track its spread. It becomes a very useful tool as we start to reduce some of our social distancing to monitor how it's spreading. It also allows us, by looking at regions that are more mutated and less mutated, to perhaps home in on some candidates for these vaccines. That genomic information can be useful to the people who are actually doing the vaccine development.
On the human side, the other $20 million is really to look at the genetic variations between patients and at how those inform their reactions, because what that might do is identify specific genes that are, for instance, more common in low-symptom patients. That could help point at potential therapeutic drug interventions, and so on, that aren't necessarily a vaccine but are rather small-molecule interventions. There are a couple of different strategies in that way.